New Technologies at Medtech Startups, October 2011

1 Min Read

Below is the list of technologies under development by startups identified and added the Medtech Startups Database during the month of October 2011:

Below is the list of technologies under development by startups identified and added the Medtech Startups Database during the month of October 2011:

  • Kidney stone retention and retrieval devices.
  • Developing a novel class of compounds for treatment of cardiovascular diseases and metabolic syndrome by exploiting novel biology, associated with mitochondria biogenesis and stabilization.
  • Undisclosed medical technology.
  • Minimally invasive spinal implant to stabilize spine and minimize twisting that can cause back pain.
  • Stroke detection and other products in neurophysiology assessment.
  • Devices to monitor gastrointestinal bleeding and related diseases.
  • Antimicrobial materials.
  • Drug-eluting implant to reduce risk of lung cancer recurrence.
  • Bioabsorbable drug-eluting stent using novel biomaterials, drug and drug delivery technology.
  • Orthopedic biologics.
  • Bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
  • Patient-controlled device that helps patients recover from knee surgery.
  • Device that stimulates production of natural tears for patients with dry eye disesse.
  • Left ventricular assist devices.

For a comprehensive list of technologies added to the database, see link.

     

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version